Physician profile
John Barry Stephens
NPI 1669663852
$16,695.41
in general payments reported to CMS, 2019-2025
35 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $1,896 · 2021: $2,807 · 2022: $2,434 · 2023: $2,765 · 2024: $2,669 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,691 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,691.03 |
| Education | $194.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,895.06 | 2019-2025 | |
| Abbvie INC. | $1,817.33 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $1,424.69 | 2019-2025 | Tremfya |
| Pfizer INC. | $1,319.22 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,280.92 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $1,250.98 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $856.11 | 2019-2025 | Bimzelx, Cimzia |
| Almirall LLC | $832.21 | 2019-2025 | Klisyri |
| Genzyme Corporation | $620.69 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $590.94 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Incyte Corporation | $576.51 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $478.85 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Leo Pharma INC. | $477.51 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $446.34 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $407.42 | 2020-2025 | Otezla, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $264.23 | 2019-2025 | |
| Dermavant Sciences, INC. | $235.74 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $146.17 | 2020-2021 | |
| Organon LLC | $108.26 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $90.11 | 2024-2025 | Sotyktu |
| Dermira, INC. | $88.15 | 2019-2020 | |
| Encore Dermatology INC. | $71.52 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $66.98 | 2021 | |
| Epi Health, LLC | $60.52 | 2020-2022 | |
| Celgene Corporation | $58.83 | 2019 | |
| Journey Medical Corporation | $50.65 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.96 | 2022 | |
| Arcutis Biotherapeutics, INC. | $32.35 | 2024-2025 | Zoryve |
| Sandoz INC. | $19.84 | 2023 | Hyrimoz |
| Prugen, INC. Pharmaceuticals | $17.85 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.08 | 2024 | Ycanth |
| Lnhc, INC | $17.05 | 2025 | Zelsuvmi |
| Aclaris Therapeutics, INC. | $15.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.31 | 2019 | |
| Mission Pharmacal Company | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.